Univariate analysis: IA treatment and follow-up tumour response (TR)
| Medication exposure | # of patients | Worse TR* | OR | 95% CI | P value |
| Systemic steroid alone | 20 | 6 | 2.54 | 0.69 to 9.32 | 0.16 |
| csDMARD | 19 | 2 | 0.34 | 0.07 to 1.74 | 0.20 |
| bDMARD | 11 | 2 | 0.82 | 0.15 to 4.43 | 0.82 |
| Any DMARD | 24 | 4 | 0.65 | 0.17 to 2.47 | 0.53 |
| NSAIDS alone | 7 | 1 | 0.61 | 0.07 to 5.58 | 0.66 |
*Worse TR: worsened tumour response on follow-up assessment as compared with baseline tumour response (eg, a patient with stable disease at baseline had progression of disease at follow-up).
bDMARD, biological disease-modifying antirheumatic drugs; csDMARD, conventional synthetic disease modifying antirheumatic drugs; IA, inflammatory arthritis; NSAIDs, non-steroidal anti-inflammatory drugs.